News

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or ...
European Medical Journal4h
Ivarmacitinib Shows Promise in Treating Severe Eczema
Discover a study that where results demonstrated significantly greater improvement in the ivarmacitinib groups compared to ...
Physician's Weekly2d
How Atopic Dermatitis Presents Differently Across Diverse Populations
Researchers reported key differences in atopic dermatitis presentation across racial groups and steps clinicians can take to ...
Alopecia Areata: Market Trends, Regulatory Framework, Clinical Trial Analysis, Epidemiology Analysis, Market Dynamics, Competitive Landscape 2025-2035
Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris ...
Medscape5d
Early Food Allergy May Increase Odds of Atopic March
Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...
Taiwan News5d
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...
Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight
The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...
Clinical Trials Arena on MSN6d
LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy
LEO Pharma has reported positive topline outcomes from the randomised Phase IIb trial of the IL-22 receptor subunit alpha 1 ...